Sources of finance for commercialization Sample Clauses

Sources of finance for commercialization. The first big customers to take up the system if it works well are the two participating end- user organizations ORBIS and MRPS. Both are working close with insurance companies for the provision of elderly homecare. Already ORBIS is chosen by CZ, a big insurance company, as the Living Lab to test eHealth solutions. In this role ORBIS will in cooperation with CZ implement eHealth solutions and test them via a model developed by CZ and ORBIS together. In this model research for the eHealth solutions will be done for patient satisfaction, the care paths, clinical efficacy, organisational and care costs. For the eHealth solutions which have good outcomes based on this research, CZ will look for structural financing via the insurance. If Miraculous-Life is successful this can also be further tested via living lab cooperation between ORBIS and CZ. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of other projects in this area. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development’ in Flevoland, the Netherlands).  Xxxxxxx, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands. This insurance company has dedicated funding (‘CZ Fonds’) for supporting such initiatives.  In the Netherlands it is becoming more common that the government or insurance companies pay for automation technology that enables elderly to live independently. Solutions such as a robotic arm or fall detection can even be part of the basic insurance if there is a medical indication22.  In Germany the most important deciding factor is the listing in the official aid catalogue (Hilfsmittelkatalog) of care insurance companies that is followed by all public insurers. In the last years various technical systems have been adde...
Sample 1Sample 2
AutoNDA by SimpleDocs
Sources of finance for commercialization. For each country represented by at least one partner within the project a list of organizations that may be interested in making use of the project outcome will be prepared. We will also investigate what the possibilities for funding for example by insurance companies can be. In case of a successful trial’s outcome, and provided the system meets the needs of residents, the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, one of the biggest insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision set-up. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of similar projects. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development in Flevoland, the Netherlands).  Xxxxxxx, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands.
Sample 1
Sources of finance for commercialization. In case of a successful trial’s outcome the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, the biggest Insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision setup. This can be a starting point of stimulating positively other insurances in other European countries in allocating budget for introducing the system in the elderly care process
Sample 1

Related to Sources of finance for commercialization

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Technology Research Analyst Job# 1810 General Characteristics

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular: (a) review and recommend the Commercialization Plans and related activities with respect to the Commercialization of Products in the Collaborator Territory, and report to the JEC on all significant Commercialization activities in the Collaborator Territory; (b) provide a forum for and facilitate communications and coordination between the Parties with respect to the Commercialization of Products in the Collaborator Territory and the Exelixis Territory; (c) on an annual basis, discuss and establish Collaborator’s Minimum Commercial Performance thresholds pursuant to Section 6.3(b) and propose recommendation to JEC; [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. (d) review the status of material Product manufacturing and supply activities and strategies associated with Commercialization; (e) review and discuss the major findings of Collaborator’s market research with respect to any Product in the Collaborator Territory, if any; (f) review and oversee the branding and product positioning strategy for Products in the Collaborator Territory and evaluate Collaborator’s brand strategy for the Product in the Collaborator Territory for consistency with the then-current global brand strategy for the Product; (g) discuss Product list price and status of reimbursement in the Collaborator Territory; and (h) perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JCC, or as otherwise directed by the JEC.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Marketing Plan The MCOP shall submit an annual marketing plan to ODM including all planned activities for promoting membership in or increasing awareness of the MCOP. The marketing plan submission shall include an attestation by the MCOP that the plan is accurate and is not intended to mislead, confuse, or defraud the eligible individuals or ODM.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!